STBK yields 16.53% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 7
Combined, STBK + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of STBK + ABBV for your $10,000?
Studio Financial Holdings, Inc. operates as the holding company for Studio Bank that provides various financial services in the United States. It offers commercial banking services, including commercial checking, and commercial savings and money market accounts; interest on lawyers trust accounts; cash concentration, remote capture, preauthorized automated clearing house debits and filtering, wire transfers, zero balance and automated sweep, account reporting and reconciliation, and positive pay services; term and bridge loans, revolving lines of credit, land development loans, construction and development lines of credit, and other commercial loans; and commercial credit cards. The company also provides personal banking services comprising personal checking and personal savings accounts; mortgages and other personal loan accounts; and personal credit cards. In addition, it offers tech and startup banking services; and mortgage and home loan options, as well as home equity lines of credit and home equity installment loans. The company operates through its offices in Davidson County, Tennessee; and a loan production office in Williamson County, Tennessee. Studio Financial Holdings, Inc. was founded in 2017 and is based in Nashville, Tennessee.
Full STBK Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.